普乐沙福在动员自体造血祖细胞患者中的有效性

[Effectiveness of plerixafor in patients undergoing mobilization autologous haematopoietic progenitor cell].

作者信息

Ruano Camps R, Ortiz Pareja M, Vidales Mancha I, Muñoz Castillo I M, Heiniger Mazo A I

出版信息

Farm Hosp. 2013 Jul-Aug;37(4):317-21. doi: 10.7399/FH.2013.37.4.656.

DOI:10.7399/FH.2013.37.4.656

PMID:24010693

Abstract

OBJECTIVE

To evaluate effectiveness of treatment with plerixafor in patients undergoing posterior mobilization for hematopoietic transplant at our hospital.

METHODS

Retrospective study of all patients who until September 2012, received plerixafor in their scheme of mobilization into peripheral blood hematopoietic progenitors. We reviewed the medical records and records of drug dispensing outpatient consultation. Effectiveness variables used were: CD34/kg in apheresis product obtained, and day dose received colony stimulating factor (G-CSF) and Plerixafor. Each patient was compared to the effectiveness of the drug results with those obtained earlier mobilization schemes where Plerixafor not used, if present. Data were analyzed using IBM SPSS v19.

RESULTS

A total of 24 patients received plerixafor in our hospital. Diagnoses were distributed: 15 NHL, 6 patients with multiple myeloma, 2 Hodgkin's disease, and one metastatic choriocarcinoma. The effectiveness outcomes were no plerixafor mobilization (n = 18): 5 patients were mobilized with G-CSGF only, 13 with G-CSF and chemotherapy. The G-CSF dose / day was mcg 931.1 (± 179.5) for 9.5 days (± 4.7). The average product obtained CD34/kg in cells was 0.2 (± 0.5). No patient received sufficient product (≥ 2 x 106 cells/kg) for subsequent autologous transplantation. 100% of the demonstrations failed. Mobilization with plerixafor (n = 24): 13 patients were mobilized with GCSGF only, 11 with G-CSF and chemotherapy. The G-CSF dose/ day and averaged Plerixafor mcg 885.1 (± 240.1) and 19.8 (± 4.4), respectively, administered for 8.9 (± 5.1) and 1 , 5 (± 0.6) days, respectively. The average product obtained in CD34/kg was 2.3 x 106 cells (± 1.7) (p = 0.014 in relation to the demonstrations without Plerixafor). Only 12.5% (n = 3) patients were unable to undergo autologous transplant.

CONCLUSIONS

In our patients, plerixafor has proven effective in mobilizing hematopoietic progenitors for autologous back.

摘要

目的

评估普乐沙福治疗我院接受造血干细胞移植后路动员患者的有效性。

方法

回顾性研究截至2012年9月所有在其外周血造血祖细胞动员方案中接受普乐沙福治疗的患者。我们查阅了病历及药物配药门诊咨询记录。使用的有效性变量为：采集产品中每千克的CD34数量、接受集落刺激因子（G-CSF）和普乐沙福的日剂量。将每位患者的药物治疗效果与早期未使用普乐沙福的动员方案所获得的效果进行比较（如有）。数据采用IBM SPSS v19进行分析。

结果

我院共有24例患者接受了普乐沙福治疗。诊断分布如下：15例非霍奇金淋巴瘤、6例多发性骨髓瘤、2例霍奇金病和1例转移性绒毛膜癌。未使用普乐沙福进行动员的效果（n = 18）：5例患者仅用G-CSGF进行动员，13例用G-CSF和化疗进行动员。G-CSF的日剂量为931.1微克（±179.5），使用9.5天（±4.7）。采集产品中每千克细胞的平均CD34数量为0.2（±0.5）。没有患者获得足够的产品（≥2×10⁶细胞/千克）用于后续自体移植。100%的样本未达标。使用普乐沙福进行动员的情况（n = 24）：13例患者仅用GCSGF进行动员，11例用G-CSF和化疗进行动员。G-CSF的日剂量和普乐沙福的平均剂量分别为885.1微克（±240.1）和19.8微克（±4.4），分别使用8.9天（±5.1）和1.5天（±0.6）。每千克采集产品中获得的平均CD34数量为2.3×10⁶细胞（±1.7）（与未使用普乐沙福的样本相比，p = 0.014）。只有12.5%（n = 3）的患者无法进行自体移植。